Fenwick & West represented AnaptysBio, Inc. (NASDAQ:ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, in its $205.5 million follow-on offering of common stock. AnaptysBio sold 3,000,000 shares of its common stock at a public offering price of $68.50 per share. In addition, AnaptysBio has granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock.
Credit Suisse, Jefferies and Stifel are acting as joint book-running managers for the offering. Wedbush PacGrow, Baird and SunTrust Robinson Humphrey are acting as co-managers.
The Fenwick transaction team was led by corporate lawyers Robert Freedman, Matthew Rossiter, Effie Toshav, Julia Forbess, Chris Walton and Elena Moreno Cloutier.